News25/Ratings0
Latest news
25 items- SECProSomnus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ProSomnus, Inc. (0001934064) (Filer)
- SECProSomnus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - ProSomnus, Inc. (0001934064) (Filer)
- SECSEC Form 10-K/A filed by ProSomnus Inc. (Amendment)10-K/A - ProSomnus, Inc. (0001934064) (Filer)
- SECSEC Form 25-NSE filed by ProSomnus Inc.25-NSE - ProSomnus, Inc. (0001934064) (Subject)
- SECProSomnus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - ProSomnus, Inc. (0001934064) (Filer)
- SECProSomnus Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - ProSomnus, Inc. (0001934064) (Filer)
- SECSEC Form 10-K filed by ProSomnus Inc.10-K - ProSomnus, Inc. (0001934064) (Filer)
- NEWSProSomnus Q4 Sales $7.84M Beat $7.37M EstimateProSomnus (NASDAQ:OSA) reported quarterly sales of $7.84 million which beat the analyst consensus estimate of $7.37 million by 6.35 percent. This is a 35.32 percent increase over sales of $5.79 million the same period last year.
- NEWS12 Health Care Stocks Moving In Tuesday's After-Market SessionGainers Apollomics (NASDAQ:APLM) stock rose 10.9% to $0.61 during Tuesday's after-market session. The market value of their outstanding shares is at $54.5 million. Cara Therapeutics (NASDAQ:CARA) shares moved upwards by 7.36% to $0.78. The company's market cap stands at $42.8 million. Coeptis Therapeutics (NASDAQ:COEP) shares moved upwards by 6.66% to $0.32. The company's market cap stands at $10.9 million. Titan Pharma (NASDAQ:TTNP) shares rose 6.44% to $7.75. The market value of their outstanding shares is at $5.8 million. BioSig Technologies (NASDAQ:BSGM) shares increased by 6.38% to $0.5. The market value of their outstanding shares is at $4.6 million. Iridex (NASDAQ:IRIX) stock in
- SECProSomnus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ProSomnus, Inc. (0001934064) (Filer)
- PRProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial ResultsPLEASANTON, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea (OSA), today announced financial results for the fourth quarter and year ended December 31, 2023. Recent Business Highlights Generated record revenues of $7.8 million for the fourth quarter and $27.7 million for the fiscal year 2023, a 35% increase compared to $5.8 million for the fourth quarter 2022 and 43% increase compared to $19.4 million for fiscal year 2022. The quarter marked the eighth (8th) sequential quarter of record revenues.Continued focus on implementing reductions in operating expenses. Operating expenses, excludin
- NEWSEarnings Scheduled For March 26, 2024Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. • AIM ImmunoTech (AMEX:AIM) is estimated to report earnings for its fourth quarter. • Elbit Systems (NASDAQ:ESLT) is projected to report quarterly earnings at $1.38 per share on revenue of $1.52 billion. • GDS Holdings (NASDAQ:GDS) is likely to report quarterly loss at $0.33 per share on revenue of $357.63 million. • Bragg Gaming Group (NASDAQ:BRAG) is estimated to report quarterly loss at $0.01 per share on revenue of $37.82 million. • BioLine Rx (NASDAQ:BLRX) is expected to report earnings for its fourth quarter. • Zhihu (NYSE:ZH) is li
- SECProSomnus Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - ProSomnus, Inc. (0001934064) (Filer)
- PRProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update CallPLEASANTON, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced today it has postponed the release of its 2023 fourth quarter and full year financial results and the related investor conference call. The rescheduled call will be held after market close on Tuesday, March 26, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Registration and dial-in information can be found on the investor relations website. Additionally, the Company will not be attending the Roth Conference. About ProSomnusProSomnus (NASDAQ: OSA) is the leading non-CPAP therapy for the treatment of Obstructiv
- NEWSTop 4 Health Care Stocks That Are Preparing To Pump This MonthThe most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. ProSomnus, Inc. (NASDAQ:OSA) On Feb. 22, ProSomnus reported successful pilot study validation of next generation remote patient m
- NEWSProSomnus Reports Successful Pilot Study Validation Of Next Generation Remote Patient Monitoring Device For Obstructive Sleep ApneaProSomnus, Inc. (NASDAQ:OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company's Next Generation Remote Patient Monitoring (RPM) device for Obstructive Sleep Apnea (OSA). Data from the pilot study demonstrated that an oximeter embedded in a precision medical device can accurately, safely, and continuously monitor SpO2. "This pilot study validation represents a step toward bringing sleep medicine into the P4 medicine era. The ProSomnus® RPMO2 OSA Device enables sleep medicine to be more personalized, predictive, preventative, and participatory," commented Len Liptak, Chief Executive Officer for ProSomnus Sleep Te
- PRProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep ApneaPLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA) (the "Company"), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company's Next Generation Remote Patient Monitoring (RPM) device for Obstructive Sleep Apnea (OSA). Data from the pilot study demonstrated that an oximeter embedded in a precision medical device can accurately, safely, and continuously monitor SpO2. "This pilot study validation represents a step toward bringing sleep medicine into the P4 medicine era. The ProSomnus® RPMO2 OSA Device enables sleep medicine to be more personalized, predictive, preventative, and participatory," commented L
- PRProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024PLEASANTON, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ:OSA), the leading non-CPAP therapy for the treatment of Obstructive Sleep Apnea (OSA), announced today that it will report its fourth quarter and fiscal year 2023 financial results and provide a business update before market open on Monday, March 18, 2024 at the 36th Annual ROTH Conference and via a live webcast. ProSomnus Chief Executive Officer, Len Liptak, and Chief Financial Officer, Brian Dow, will host a conference call at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Following the call, management will participate in the 36th Annual ROTH Conference, being held March 17-19, 2024. Fourth Quarter and Fisc
- INSIDERKim Sung was granted 315,742 shares, increasing direct ownership by 157% to 516,808 units (SEC Form 4)4 - ProSomnus, Inc. (0001934064) (Issuer)
- INSIDERDow Brian B was granted 315,742 shares, increasing direct ownership by 337% to 409,492 units (SEC Form 4)4 - ProSomnus, Inc. (0001934064) (Issuer)
- INSIDERLiptak Len was granted 1,322,756 shares, increasing direct ownership by 208% to 1,957,216 units (SEC Form 4)4 - ProSomnus, Inc. (0001934064) (Issuer)
- INSIDERNew insider Rikkers Laing claimed ownership of 354,392 shares (SEC Form 3) (Amendment)3/A - ProSomnus, Inc. (0001934064) (Issuer)
- INSIDERNew insider Rider Heather claimed ownership of 9,100 shares (SEC Form 3) (Amendment)3/A - ProSomnus, Inc. (0001934064) (Issuer)
- INSIDERNew insider Pacelli Steven Robert claimed ownership of 18,200 shares (SEC Form 3) (Amendment)3/A - ProSomnus, Inc. (0001934064) (Issuer)
- INSIDERNew insider Johnson William S. claimed ownership of 76,526 shares (SEC Form 3) (Amendment)3/A - ProSomnus, Inc. (0001934064) (Issuer)
OSA FAQ
4 questionsWhere does OSA stock trade?
ProSomnus Inc. (OSA) is listed on NASDAQ.What sector and industry is OSA in?
ProSomnus Inc. operates in the Health Care sector, Medical Specialities industry.What companies are similar to OSA?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare OSA side-by-side with any of them on Quantisnow.How can I track OSA on Quantisnow?
Quantisnow aggregates ProSomnus Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow OSA to receive live email and push alerts on every new disclosure.